Dori Thomas-Karyat

Company: Synthis Therapeutics

Job title: Chief Executive Officer

Seminars:

Using Antibody-Drug Conjugates to Selectively Inhibit Disease-Driving TGF-β Isoforms & Cells 1:30 pm

Introduce a novel therapeutic approach to target the TGF-β pathway, a key driver of fibrosis, while improving efficacy, safety, and patient outcomes through selective inhibition Discuss the design and development of cell-targeted ADCs that inhibit TGF-β in pathogenic cell populations, enhancing on-target specificity and minimizing off-target effects compared to systemic therapies Explore the utility of…Read more

day: Conference Day Two